Cargando…
Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?
Tumour therapy with cyclophosphamide (CPA), an alkylating chemotherapeutic agent, has been associated with reduced tumour blood supply and antiangiogenic effects when applied in a continuous, low-dose metronomic schedule. Compared to conventional high-dose scheduling, metronomic CPA therapy exhibits...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828885/ https://www.ncbi.nlm.nih.gov/pubmed/18266977 http://dx.doi.org/10.1111/j.1582-4934.2008.00255.x |
_version_ | 1782291301741363200 |
---|---|
author | Günther, M Wagner, E Ogris, M |
author_facet | Günther, M Wagner, E Ogris, M |
author_sort | Günther, M |
collection | PubMed |
description | Tumour therapy with cyclophosphamide (CPA), an alkylating chemotherapeutic agent, has been associated with reduced tumour blood supply and antiangiogenic effects when applied in a continuous, low-dose metronomic schedule. Compared to conventional high-dose scheduling, metronomic CPA therapy exhibits antitumoural activity with reduced side effects. We have studied potential antiangiogenic properties of acrolein which is released from CPA after hydroxylation. Acrolein adducts were found in tumour cells and tumour endothelial cells of CPA-treated mice, suggesting an in vivo relevance of acrolein. In vitro, acrolein inhibited endothelial cell proliferation, endothelial cell migration and tube formation. Moreover, acrolein caused disassembly of the F-actin cytoskeleton and inhibition of αvβ3 integrin clustering at focal adhesions points in endothelial cells. Acrolein treatment modulated expression of thrombospondin-1 (TSP-1), an endogenous inhibitor of angiogenesis known to be linked to antiangiogenic effects of metronomic CPA therapy. Further on, acrolein treatment of primary endothelial cells modified NF-(κ)B activity levels. This is the first study that points at an antiangiogenic activity of acrolein in metronomically scheduled CPA therapy. |
format | Online Article Text |
id | pubmed-3828885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-38288852015-04-27 Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? Günther, M Wagner, E Ogris, M J Cell Mol Med Articles Tumour therapy with cyclophosphamide (CPA), an alkylating chemotherapeutic agent, has been associated with reduced tumour blood supply and antiangiogenic effects when applied in a continuous, low-dose metronomic schedule. Compared to conventional high-dose scheduling, metronomic CPA therapy exhibits antitumoural activity with reduced side effects. We have studied potential antiangiogenic properties of acrolein which is released from CPA after hydroxylation. Acrolein adducts were found in tumour cells and tumour endothelial cells of CPA-treated mice, suggesting an in vivo relevance of acrolein. In vitro, acrolein inhibited endothelial cell proliferation, endothelial cell migration and tube formation. Moreover, acrolein caused disassembly of the F-actin cytoskeleton and inhibition of αvβ3 integrin clustering at focal adhesions points in endothelial cells. Acrolein treatment modulated expression of thrombospondin-1 (TSP-1), an endogenous inhibitor of angiogenesis known to be linked to antiangiogenic effects of metronomic CPA therapy. Further on, acrolein treatment of primary endothelial cells modified NF-(κ)B activity levels. This is the first study that points at an antiangiogenic activity of acrolein in metronomically scheduled CPA therapy. Blackwell Publishing Ltd 2008-12 2008-02-06 /pmc/articles/PMC3828885/ /pubmed/18266977 http://dx.doi.org/10.1111/j.1582-4934.2008.00255.x Text en © 2008 The Authors Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd |
spellingShingle | Articles Günther, M Wagner, E Ogris, M Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? |
title | Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? |
title_full | Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? |
title_fullStr | Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? |
title_full_unstemmed | Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? |
title_short | Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? |
title_sort | acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828885/ https://www.ncbi.nlm.nih.gov/pubmed/18266977 http://dx.doi.org/10.1111/j.1582-4934.2008.00255.x |
work_keys_str_mv | AT guntherm acroleinunwantedsideproductorcontributiontoantiangiogenicpropertiesofmetronomiccyclophosphamidetherapy AT wagnere acroleinunwantedsideproductorcontributiontoantiangiogenicpropertiesofmetronomiccyclophosphamidetherapy AT ogrism acroleinunwantedsideproductorcontributiontoantiangiogenicpropertiesofmetronomiccyclophosphamidetherapy |